Exosomes; Nano-Scale Bubbles Creating Waves in Diagnostics and Therapeutics - Seite 2

Currently the research market for exosomes is about $50 million but this does not account for the opportunities in the diagnostics space which will drive market growth and value creation."

Aethlon Medical (OTCBB: AEMD) is one of the only companies that may be able to participate in both diagnostics and therapeutics in the exosome space. The company recently announced the launch of Exosome Sciences (ESI) as a subsidiary that is advancing exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. Aethlon also attracted two of the best-known thought leaders in the exosome industry to play key roles in the new company. 

"We are well positioned to benefit from the exosome revolution," stated Aethlon Medical Chairman and CEO, Jim Joyce. "We are advancing patented first-in-class therapeutic technology to eliminate the presence of tumor-secreted exosomes that trigger the death of immune cells necessary for combating cancer. On the diagnostic front, our Exosome Sciences research team pioneered the field of exosome biology and is actively advancing a pipeline of next generation diagnostic tools."

In September of this year, Exosome Diagnostics announced that it entered into a collaboration agreement with Eli Lilly & Co. "Exosome Diagnostics technology may provide a unique opportunity to gain insight into the biology of complex conditions such as cancer and immune disorders," stated Andrew Schade, Senior Medical Director, Diagnostic and Experimental Pathology at Eli Lilly. He further stated that "Exosome technology enables biofluid molecular sampling and the ability to monitor disease progression in real time. As Lilly explores new ways to pursue patient tailoring, we'll continue to work with partners to expand our capabilities."

Another company in the space, stem cell therapy development company ReNeuron reported in early December, "We have highlighted a number of key developments in the period, notably the successful and earlier-than-planned development of a second-generation cryopreserved CTX drug product for our stroke and critical limb ischaemia programmes, our planned world-class cell manufacturing facility in South Wales, the granting of Orphan Drug Designation for our retinitis pigmentosa programme and the accelerated development of our CTX cell-based exosomes therapeutic platform."